Bronchial Asthma: Current Trends in Treatment
By:
References
- 1. Chung KF. Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies. J Intern Med 2016; 279: 192-204.
- 2. Bush A. Pathophysiological Mechanisms of Asthma. Front Pediatr 2019; 7: 68.
- 3. Upham JW, Chung LP. Optimising treatment for severe asthma. Med J Aust 2018; 209: S22-7.
- 4. Reddel HK, FitzGerald JM, Bateman ED, et al. GINA 2019: a fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. Eur Respir J 2019; 53: pii: 1901046.
- 5. Muneswarao J, Hassali MA, Ibrahim B, et al. It is time to change the way we manage mild asthma: an update in GINA 2019. Respir Res 2019; 20: 183.
- 6. Adcock IM, Lane SJ. Corticosteroid-insensitive asthma: molecular mechanisms. J Endocrinol 2003; 178: 347-55.
- 7. Vrlik M, Dzurilla M, Bucova M, Kantarova D, Buc M. Asthma bronchiale phenotypes and their treat ment. a current view. Acta Med Mart 2009; 9: 3-11.
- 8. Wenzel S. Severe asthma: from characteristics to phenotypes to endotypes. Clin Exp Allergy 2012; 42: 650-8.
- 9. Esteban-Gorgojo I, Antolín-Amérigo D, Domínguez-Ortega J, Quirce S. Non-eosinophilic asthma: current perspectives. J Asthma Allergy 2018; 11: 267-81.
- 10. Kudo M, Ishigatsubo Y, Aoki I. Pathology of asthma. Front Microbiol 2013; 4: 263.
- 11. Katial RK, Bensch GW, Busse WW, et al. Changing Paradigms in the Treatment of Severe Asthma: The Role of Biologic Therapies. J Allergy Clin Immunol Pract 2017; 5: S1-14.
- 12. Humbert M, Busse W, Hanania NA, et al. Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract 2014; 2: 525-36.
- 13. Bel EH, Ten Brinke A. New Anti-Eosinophil Drugs for Asthma and COPD: Targeting the Trait! Chest 2017; 152: 1276-82.
- 14. Godar M, Blanchetot C, De Haard H, et al. Personalized medicine with biologics for severe type 2 asthma: current status and future prospects. MAbs 2018; 10: 34-45.
- 15. Pelaia C, Vatrella A, Busceti MT, et al. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab. Drug Des Devel Ther 2017; 11: 3137-44.
- 16. Lim HF, Nair P. Efficacy and safety of reslizumab in patients with moderate to severe eosinophilic asthma. Expert Rev Respir Med 2015; 9: 135e142.
- 17. Nowak RM, Parker JM, Silverman RA, et al. A randomized trial of benralizumab, an anti inter -leukin 5 receptor a monoclonal antibody, after acute asthma. Am J Emerg Med 2015; 33: 14e20.
- 18. Bagnasco D, Ferrando M, Varricchi G, et al. A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma. Int Arch Allergy Immunol 2016; 170: 122-31.
- 19. Walsh GM. An update on biologic-based therapy in asthma. Immunotherapy 2013; 5: 1255-64.
- 20. Bernstein JA, Panettieri R. Treatment of severe, uncontrolled eosinophilic asthma: Where we are heading. J Asthma 2019; 56: 459-72.
- 21. Hanania NA, Korenblat P, Chapman KR, et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med 2016; 4: 781-96.
- 22. Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013; 368: 2455–66.
- 23. Antoniu SA. Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema. Curr Opin Investig Drugs 2010; 11: 1286-94.
- 24. Stokes JR, Casale TB. Characterization of asthma endotypes: implications for therapy. Ann Allergy Asthma Immunol 2016; 117: 121-5.
- 25. White C, Wright A, Brightling C. Fevipiprant in the treatment of asthma. Expert Opin Investig Drugs 2018; 27: 199-207.
- 26. Al-Sajee D, Oliveria JP, Sehmi R, Gauvreau GM. Antialarmins for treatment of asthma: future perspectives. Curr Opin Pulm Med 2018; 24: 32-41.
- 27. Gauthier M, Ray A, Wenzel SE. Evolving Concepts of Asthma. Am J Respir Crit Care Med 2015; 192: 660-8.
- 28. Nair P, Aziz-Ur-Rehman A, Radford K. Therapeutic implications of ‘neutrophilic asthma’. Curr Opin Pulm Med 2015; 21: 33-8.
- 29. Nair P, Gaga M, Zervas E, et al. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin Exp Allergy 2012; 42: 1097-103.
- 30. Busse WW, Holgate S, Kerwin E, et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med 2013; 188: 1294-302.
- 31. Divekar R, Lal D. Recent advances in biologic therapy of asthma and the role in therapy of chronic rhinosinusitis. F1000Res 2018; 7: 412.
- 32. Howarth PH, Babu KS, Arshad HS, et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005; 60: 1012-8.
- 33. Wenzel SE, Barnes PJ, Bleecker ER, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009; 179: 549-58.
- 34. Erzurum SC. Inhibition of tumor necrosis factor alpha for refractory asthma. N Engl J Med 2006; 354: 754-8.
- 35. Morjaria JB, Chauhan AJ, Babu KS, et al. The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. Thorax 2008; 63: 584-91
- 36. Holgate ST, Noonan M, Chanez P, et al. Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial. Eur Respir J 2011; 37: 1352-9.
- 37. Brightling C, Berry M, Amrani Y. Targeting TNF-alpha: a novel therapeutic approach for asthma. J Allergy Clin Immunol 2008; 121: 5-10.
- 38. Chu DK, Al-Garawi A, Llop-Guevara A, et al. Therapeutic potential of anti-IL-6 therapies for granulocytic airway inflammation in asthma. Allergy Asthma Clin Immunol 2015; 11:14.
- 39. Garth J, Barnes JW, Krick S. Targeting Cytokines as Evolving Treatment Strategies in Chronic Inflammatory Airway Diseases. Int J Mol Sci 2018; 19: pii E3402.
- 40. Chaudhuri R, Norris V, Kelly K, et al. Effects of a FLAP inhibitor, GSK2190915, in asthmatics with high sputum neutrophils. Pulm Pharmacol Ther 2014; 27: 62-9.
- 41. Gibson PG, Yang IA, Upham JW, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet 2017; 390: 659-68.
- 42. Schögler A, Kopf BS, Edwards MR, et al. Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells. Eur Respir J 2015; 45: 428-39.
- 43. Essilfie AT, Horvat JC, Kim RY, et al. Macrolide therapy suppresses key features of experimental steroid-sensitive and steroid-insensitive asthma. Thorax 2015; 70: 458-67.
- 44. Barnes PJ. New therapies for asthma: is there any progress? Trends Pharmacol Sci 2010; 31: 335-43.
- 45. So JY, Dhungana S, Beros JJ, Criner GJ. Statins in the treatment of COPD and asthma-where do we stand? Curr Opin Pharmacol 2018; 40: 26-33.
- 46. Barnes PJ. Kinases as Novel Therapeutic Targets in Asthma and Chronic Obstructive Pulmonary Disease. Pharmacol Rev 2016; 68: 788-815.
- 47. Barnes PJ. Severe asthma: advances in current management and future therapy. J Allergy Clin Immunol 2012; 129: 48-59.
- 48. Schuliga M. NF-kappaB Signaling in Chronic Inflammatory Airway Disease. Biomolecules 2015; 5: 1266-83.
- 49. Cousins DJ, Mcdonald J, Lee TH. Therapeutic approaches for control of transcription factors in allergic disease. J Allergy Clin Immunol 2008; 121: 803-9.
- 50. Garn H, Renz H. GATA-3-specific DNAzyme - A novel approach for stratified asthma therapy. Eur J Immunol 2017; 47: 22-30.
- 51. Krug N, Hohlfeld JM, Kirsten AM, et al. Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. N Engl J Med 2015; 372: 1987-95.
- 52. Valladao AC, Frevert CW, Koch LK, Campbell DJ, Ziegler SF. STAT6 Regulates the Development of Eosinophilic versus Neutrophilic Asthma in Response to Alternaria alternata. J Immunol 2016; 197: 4541-51.
- 53. Nirmathan T, Medvedova I, Eichlerova A, Prso M, Mokra D, Mokry J. Effects of roflumilast, selective PDE4 inhibitor, on airway reactivity in ovalbumin-sensitized guinea pigs. Acta Med Mart 2015; 15: 12-19.
- 54. Mokry J, Mokra D. Immunological aspects of phosphodiesterase inhibition in the respiratory system. Respir Physiol Neurobiol 2013; 187: 11-7.
- 55. Mariotti F, Govoni M, Lucci G, Santoro D, Nandeuil MA. Safety, tolerability, and pharmacokinetics of single and repeat ascending doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor: two randomized trials in healthy volunteers. Int J Chron Obstruct Pulmon Dis 2018; 13: 3399-410.
- 56. Christensen I, Miskovicova H, Porvaznik I, Joskova M, Mokra D, Mokry J. Selective inhibition of phosphodiesterase 7 (PDE7) by BRL50481 in healthy and ovalbumin-sensitized guinea pigs. Acta Med Mart 2012; 12 (Suppl 1): 16-23.
- 57. Antošová M, Strapková A., Nosáľová G, Fraňová S. Inhibitors of nitric oxide synthases and exogenous irritant-induced bronchial hyperreactivity. Acta Med Mart 2004; 4: 3-8.
- 58. Varcholová L, Tobiášová Z, Fraňová S. The role of nitric oxide in bronchodilatory effects of Provinol – the red wine polyphenolic compounds. Acta Med Mart 2003; 3: 17-22.
- 59. Barnig C, Frossard N, Levy BD. Towards targeting resolution pathways of airway inflammation in asthma. Pharmacol Ther 2018; 186: 98-113.
Language: English
Page range: 9 - 17
Submitted on: Oct 28, 2019
Accepted on: Dec 6, 2019
Published on: Apr 30, 2020
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 3 times per year
Keywords:
Related subjects:
© 2020 R Palova, J Adamcakova, D Mokra, J Mokry, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.